Literature DB >> 10467278

Splenectomy during partial remission in thrombotic thrombocytopenic purpura with prolonged plasma exchange dependency.

M J Mant1, A R Turner, D Bruce, C Ritchie, L M Larratt.   

Abstract

Some patients with thrombotic thrombocytopenic purpura (TTP) remain plasma-exchange-dependent for prolonged periods of time. This exposes patients to risk, uses substantial resources, and requires prolonged hospitalization. We have splenectomized 7 such patients following 25-42 plasma exchanges while patients were in partial remission only and were clinically stable. In 6 patients, including 1 with TTP secondary to mitomycin C, thrombocytopenia promptly resolved. Relapse has not occurred during 18 or more months of observation. The seventh patient did not respond. We conclude that splenectomy should be considered as an alternative to continued plasma-exchange therapy in such patients. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10467278     DOI: 10.1002/(sici)1096-8652(199909)62:1<56::aid-ajh10>3.0.co;2-5

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  3 in total

Review 1.  Case series: splenectomy: does it still play a role in the management of thrombotic thrombocytopenic purpura?

Authors:  Luc Dubois; Daryl K Gray
Journal:  Can J Surg       Date:  2010-10       Impact factor: 2.089

2.  Laparoscopic splenectomy for the treatment of refractory thrombotic thrombocytopenic purpura.

Authors:  Akira Umemura; Akira Sasaki; Hiroyuki Nitta; Toru Obuchi; Shigeaki Baba; Go Wakabayashi
Journal:  Clin J Gastroenterol       Date:  2013-09-07

3.  Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng; Sara K Vesely; Spero R Cataland; Paul Coppo; Brian Geldziler; Alfonso Iorio; Masanori Matsumoto; Reem A Mustafa; Menaka Pai; Gail Rock; Lene Russell; Rawan Tarawneh; Julie Valdes; Flora Peyvandi
Journal:  J Thromb Haemost       Date:  2020-09-11       Impact factor: 5.824

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.